|
|
Detection of serum antibody levels after inoculation of an inactivated SARS-CoV-2 vaccine |
XU Nani1, HU Xiaowei1, LI Haiyan2, ZHENG Lin1, KONG Qingxin3, QIN Pan1, LI Jing1, YE Fei4
|
1. Department of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, Zhejiang 310030, China; 2. Hangzhou Di'an Medical Laboratory Co., Ltd, Hangzhou, Zhejiang 310012, China; 3. Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang 310021, China; 4. Hangzhou Xixi Hospital, Hangzhou, Zhejiang 310023, China |
|
|
Abstract Objective To investigate the serum levels of antibodies against SARS-CoV-2 after inoculation of an inactivated SARS-CoV-2 vaccine, so as to provide insights into the evaluation of the vaccine immunogenicity. Methods In this single-arm Objective performance criteria trial, residents aged 18 to 59 years and inoculated with an inactivated SARS-CoV-2 vaccine in Xihu District, Hangzhou City from October to December of 2020 were selected using a cluster sampling method. Blood samples were collected prior to inoculation, 14 and 28 days post-inoculation of the first dose, and 28 days post-inoculation of the second dose. Serum levels of anti-SARS-CoV-2 IgM and IgG antibodies were detected using the magnetic particle-based chemiluminescence immunoassay. The seroconversion of antibodies and dynamic changes of antibody levels were analyzed. Results Totally 310 participants were enrolled, including 133 subjects on day 14 post-inoculation of the first dose, 97 subjects on day 28 post-inoculation of the first dose and 254 subjects on day 28 post-inoculation of the second dose. The seroconversion rates of anti-SARS-CoV-2 IgG antibody were 6.02%, 28.87% and 98.43%, and the median IgG antibody levels were 1.76 ( interquartile range, 3.25 ), 5.69 ( 9.95 ) and 52.05 ( 47.60 ) AU/mL ( P<0.05 ), respectively, while the seroconversion rates of anti-SARS-CoV-2 IgM antibody were 9.02%, 11.34% and 12.99%, and the median IgG antibody levels were 1.89 ( 3.28 ), 2.06 ( 4.71 ) and 2.65 ( 4.01 ) AU/mL ( P>0.05 ), respectively. In addition, higher serum levels of anti-SARS-CoV-2 IgG and IgM antibodies were detected post-inoculation relative to pre-inoculation ( P<0.05 ), and higher serum IgG antibody levels were found in subjects aged 18 to 39 years than in those aged 40 to 59 years ( P<0.05 ). Conclusions Inoculation of two doses of the inactivated SARS-CoV-2 vaccine achieves a high immunogenicity among residents aged 18 to 59 years 28 days post-inoculation, and the anti-SARS-CoV-2 IgM antibody is detectable in some residents following inoculation of the first dose.
|
Received: 24 August 2021
Revised: 15 October 2021
Published: 12 January 2022
|
|
|
|
|
[1] 中华人民共和国国家卫生健康委员会.新冠病毒疫苗接种情况[EB/OL].(2021-10-14)[2021-10-15].http://www.nhc.gov.cn/jkj/s7915/202110/1fca4cdedd084cde8de3089fd51fa254.shtml. National Health Commission of the People's Republic of China.Information about COVID-19 vaccination[EB/OL].(2021-10-14)[2021-10-15].http://www.nhc.gov.cn/jkj/s7915/202110/1fca4cdedd084cde8de3089fd51fa254.shtml. [2] WU A P,PENG Y S,HUANG B Y,et al.Genome composition and divergence of the novel coronavirus(2019-nCoV)originating in China[J].Cell Host Microbe,2020,27(3):325-328. [3] DAI L,GAO G F. Viral targets for vaccines against COVID-19[J/OL]. Nat Rev Immunol(2020-12-18)[2021-10-15]. https://doi.org/10.1038/s41577-020-00480-0. [4] 朱瑶,韦意娜,孙畅,等.新型冠状病毒肺炎疫苗研究进展[J].预防医学,2021,33(2):143-148. ZHU Y,WEI Y N,SUN C,et al.Development of vaccines against COVID-19[J]. Prev Med,2021,33(2):143-148. [5] XIA S L,ZHANG Y T,WANG Y X,et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J].Lancet Infect Dis,2020,21(1):39-51. [6] ZHANG Y J,ZENG G,PAN H X,et al.Safety,tolerability,and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years:a randomised,double-blind,placebo-controlled,phase 1/2 clinical trial[J].Lancet Infect Dis,2021,21(2):181-192. [7] 陈维欣,陈萌,周珊珊,等.新型冠状病毒疫苗免疫后抗体水平检测的3种实验方法比较[J].中华微生物学和免疫学杂志,2021,41(6):423-426. CHEN W X,CHEN M,ZHOU S S,et al.Comparison of three methods to detect antibody response to SARS-CoV-2 vaccine[J].Chin J Microbiol Immunol,2021,41(6):423-426. [8] 赵宏婷,彭质斌,杨孝坤,等.新型冠状病毒感染者特异性抗体动态变化特征研究进展[J].中华流行病学杂志,2021,42(1):39-43. ZHAO H T,PENG Z B,YANG X K,et al.Progress in research of specific antibody dynamic characteristics in patients with COVID-19[J].Chin J Epidemiol,2021,42(1):39-43. [9] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.关于印发新型冠状病毒肺炎防控方案(第八版)的通知[EB/OL].(2021-05-14)[2021-10-15].http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm. The Joint Prevention and Control Mechanism of the State Council of the People's Republic of China. Notice on the publication of COVID-19 Prevention and Control Programme(eighth edition)[EB/OL].(2021-05-14)[2021-10-15].http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm. |
|
|
|